Stocks and Investing
Stocks and Investing
Mon, April 10, 2023
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
Fri, April 7, 2023
[ Fri, Apr 07th 2023
] - WOPRAI
Thu, April 6, 2023
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
[ Thu, Apr 06th 2023
] - WOPRAI
Brian Abrahams Maintained (VRTX) at Hold and Held Target at $299 on, Apr 6th, 2023
Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold and Held Target at $299 on, Apr 6th, 2023.
Brian has made no other calls on VRTX in the last 4 months.
There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 5 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $300 on, Thursday, February 9th, 2023
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Increased Target to $312 on, Wednesday, February 8th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $285 on, Wednesday, February 8th, 2023
- Do Kim of "Piper Sandler" Maintained at Hold and Held Target at $296 on, Wednesday, February 8th, 2023
- Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $340 on, Monday, December 19th, 2022
These are the ratings of the 7 analyists that currently disagree with Brian
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, March 29th, 2023
- William Pickering of "Bernstein" Initiated at Buy and Held Target at $344 on, Tuesday, March 21st, 2023
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $326 on, Wednesday, February 8th, 2023
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $375 on, Wednesday, February 8th, 2023
- David Risinger of "SVB Leerink" Maintained at Buy with Decreased Target to $365 on, Wednesday, February 8th, 2023
- Evan Seigerman of "BMO Capital" Maintained at Buy and Held Target at $355 on, Wednesday, February 8th, 2023
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $342 on, Wednesday, February 8th, 2023
Contributing Sources